Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia
NCT ID: NCT05881265
Last Updated: 2025-02-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
30 participants
INTERVENTIONAL
2023-05-15
2026-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL
NCT01987297
Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic Leukemia
NCT07187505
Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients
NCT07159620
A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia
NCT02200978
VAC Regimen for AML Patients Who Failed to Response to VA Regimen
NCT06220162
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Chi-Ven treatment
Patients receive chidamide and venetoclax treatment
Chidamide+venetoclax
Chidamide 30mg BIW x 4 weeks; Venetoclax 100mg D1, 200mg D2 and 400mg D3-28
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Chidamide+venetoclax
Chidamide 30mg BIW x 4 weeks; Venetoclax 100mg D1, 200mg D2 and 400mg D3-28
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients in non-remission status after treatment of RA combined with As
* Patients with life expectance \>=3 months
* Inform consent provided
Exclusion Criteria
* Patients with life-expectancy less than 2 months
* Patients with abnormal liver (\>3XN) and renal function (\>3XN）
16 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Clinical Research Center
UNKNOWN
Shanghai Jiao Tong University School of Medicine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jiong HU
Head, Blood & Marrow Transplantation Center, Rui Jin Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Chun Wang
Role: STUDY_DIRECTOR
Zhaxin Hospital, Go Broad Health Care
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Affiliated Huai An No 1 Perople's Hospital of NanJing University
Huai'an, Jiangsu, China
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
Jiong HU
Shanghai, Shanghai Municipality, China
Zhaxin Hospital, Go Broad Health Care
Shanghai, Shanghai Municipality, China
NanFang Hospital
Guangzhou, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Wenhua Zhou
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
R/R-APL-2023
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.